BUSINESS● LOW1h ago · Nov 3, 2026, 2:29 AM
Syndax anticipates Revuforj could exceed $2B in U.S. peak annual net revenue as post-transplant maintenance builds
Seeking Alpha Tech · north america
Syndax projects that its drug Revuforj could achieve over $2 billion in peak annual net revenue in the U.S., driven by its use in post-transplant maintenance. This highlights the company's expectations for a key product's market performance.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS12m agoSBA Communications declares $1.25 dividendSeeking Alpha TechBUSINESS13m agoAustralia hikes rates to 18-year high to fight inflationCNBC